Global Premenstrual Dysphoric Disorder Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Premenstrual Dysphoric Disorder Market Size

• The global premenstrual dysphoric disorder market size was valued at USD 351.00 Million in 2024 and is expected to reach USD 469.39 Million by 2032, at a CAGR of 3.70% during the forecast period
• The market growth is largely fueled by the increasing awareness and diagnosis rates of premenstrual dysphoric disorder (PMDD), along with advancements in targeted treatment options, leading to improved patient outcomes and a higher demand for therapeutic solutions in both developed and emerging markets
• Furthermore, rising consumer demand for effective, safe, and accessible PMDD treatments—combined with growing support from healthcare providers and advocacy groups—is establishing specialized PMDD therapies as a preferred choice for women’s mental and reproductive health. These converging factors are accelerating the uptake of premenstrual dysphoric disorder solutions, thereby significantly boosting the industry's growth

Premenstrual Dysphoric Disorder Market Analysis

• Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome characterized by significant mood disturbances, such as irritability, depression, and anxiety, which can substantially impact daily functioning. The market is witnessing steady growth due to increasing awareness of PMDD, improved diagnostic capabilities, and the rising adoption of effective treatment options such as antidepressants, hormonal therapies, and nutritional supplements
• The growing emphasis on women’s mental health, expanding healthcare access, and greater education on menstrual health are driving demand for PMDD treatments worldwide
• North America dominated the premenstrual dysphoric disorder market with the largest revenue share of 40.5% in 2024, supported by strong healthcare infrastructure, higher diagnosis rates, and a growing acceptance of mental health treatments. The U.S. remains the largest contributor in the region due to proactive screening programs, the presence of key pharmaceutical companies, and strong insurance coverage for mental health conditions
• Asia-Pacific is projected to be the fastest-growing region in the premenstrual dysphoric disorder market during the forecast period, with an expected CAGR from 2025 to 2032, driven by increasing awareness of PMDD, growing investments in women’s health programs, and improving access to hormonal and psychiatric care in countries such as China, India, and Japan
• The oral route dominated the premenstrual dysphoric disorder market with a market share of 71.4% in 2024, supported by its convenience, non-invasiveness, and high patient adherence for daily or intermittent therapy

Report Scope and Premenstrual Dysphoric Disorder Market Segmentation  

Premenstrual Dysphoric Disorder Market Trends

Rising Awareness and Focus on Women’s Mental Health

• A significant and accelerating trend in the global premenstrual dysphoric disorder (PMDD) market is the growing recognition of PMDD as a serious mental health condition, distinct from general premenstrual syndrome (PMS). Increased advocacy by women’s health organizations, social media campaigns, and educational programs is boosting awareness and diagnosis rates worldwide
• For instance, in recent years, various women’s health NGOs and governmental bodies have launched public health initiatives aimed at improving early detection of PMDD, ensuring that women receive timely psychiatric and hormonal interventions
• The rising emphasis on mental health parity in insurance policies is driving better treatment accessibility. In countries such as the U.S., U.K., and Australia, expanded mental health coverage has resulted in higher prescription rates for SSRIs, SNRIs, and hormonal therapies tailored to PMDD
• Pharmaceutical companies are increasingly investing in research to develop more effective, targeted therapies with fewer side effects, including next-generation hormonal treatments and fast-acting antidepressants specifically designed for luteal-phase dosing
• The integration of telemedicine into gynecological and psychiatric care is enabling broader access to PMDD diagnosis and treatment, particularly in rural or underserved areas. Online consultations and prescription delivery services are making treatment more convenient for patients
• This trend toward greater awareness, earlier intervention, and diversified treatment options is reshaping patient expectations for PMDD care. Consequently, both established pharmaceutical firms and emerging biotech companies are exploring innovative formulations, lifestyle interventions, and complementary therapies to meet growing demand
• The demand for effective PMDD treatment is expanding rapidly across both developed and emerging markets, driven by increasing healthcare access, reduced stigma surrounding mental health, and a global push for better women’s health outcomes

Premenstrual Dysphoric Disorder Market Dynamics

Driver

Growing Need for Effective Treatment Options Due to Rising Awareness and Diagnosis Rates

• The increasing recognition of premenstrual dysphoric disorder (PMDD) as a serious and debilitating condition is driving the demand for effective treatment solutions. Enhanced diagnostic capabilities, along with growing awareness among both healthcare professionals and patients, are significantly contributing to market growth
• For instance, in March 2024, Eli Lilly and Company announced the initiation of a Phase III clinical trial evaluating the efficacy of a novel serotonin reuptake inhibitor specifically designed for PMDD patients, aiming to provide faster onset of symptom relief. Such strategic developments are expected to boost the PMDD treatment market in the coming years
• As more women seek medical advice for severe premenstrual symptoms, there is a rising demand for targeted therapies such as antidepressants, hormone therapy, and lifestyle management programs. This increased patient engagement is driving pharmaceutical innovation and expanding the overall treatment portfolio
• Furthermore, the growing presence of online mental health platforms and telemedicine is improving access to PMDD diagnosis and treatment, especially in underserved or rural areas, supporting global market expansion
• The emphasis on holistic care approaches, including diet, exercise, and psychological counseling alongside medication, is also gaining traction, reflecting the trend toward patient-centered treatment models

Restraint/Challenge

Limited Awareness in Developing Regions and Side Effects of Existing Therapies

• Despite growing awareness in developed economies, limited recognition of PMDD in many developing regions hampers timely diagnosis and treatment. Cultural stigma around menstrual and mental health issues often prevents women from seeking medical help
• For instance, research published in the Journal of Women's Health (2023) indicated that awareness levels of PMDD remain below 25% in several low- and middle-income countries, leading to underreporting and underdiagnosis
• Another key challenge is the side effect profile of current treatment options. Selective serotonin reuptake inhibitors (SSRIs), for example, may cause nausea, insomnia, and sexual dysfunction, while hormone therapies can lead to weight gain, mood fluctuations, and cardiovascular risks
• Addressing these challenges requires public health education campaigns, culturally sensitive awareness programs, and the development of therapies with improved safety and tolerability. Companies such as Bayer AG and GlaxoSmithKline plc are already investing in next-generation formulations aimed at reducing side effects while maintaining efficacy
• Cost accessibility also remains a hurdle, particularly in emerging markets, where high-priced branded medications can limit patient reach. Affordable generics and insurance coverage expansion will be key in overcoming this barrier and ensuring equitable access to care

Premenstrual Dysphoric Disorder Market Scope

The market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end user and distribution channel.

• By Treatment

On the basis of treatment, the premenstrual dysphoric disorder market is segmented into antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, hormone therapy, exercise, diet, and others. The antidepressants segment dominated the largest market revenue share of 42.5% in 2024, driven by the high efficacy of selective serotonin reuptake inhibitors (SSRIs) in alleviating mood-related symptoms such as depression, irritability, and anxiety. The increasing preference for SSRIs such as fluoxetine and sertraline stems from their ability to provide rapid relief during the luteal phase, coupled with favorable prescribing guidelines in multiple countries.

The hormone therapy segment is expected to witness the fastest CAGR of 9.8% from 2025 to 2032, fueled by advancements in hormonal modulation techniques, including the use of oral contraceptives and gonadotropin-releasing hormone (GnRH) agonists. These therapies aim to stabilize hormonal fluctuations that trigger PMDD symptoms, with growing adoption among patients unresponsive to antidepressants.

• By Diagnosis

On the basis of diagnosis, the premenstrual dysphoric disorder market is segmented into physical examination and others. The physical examination segment held the largest market share of 58.6% in 2024, driven by the rising emphasis on accurate symptom tracking and clinical assessment. Physicians often rely on detailed menstrual cycle history, symptom diaries, and physical evaluations to differentiate PMDD from other mood disorders, ensuring targeted treatment.

The others category (psychological evaluation tools and hormone level assessments) is anticipated to grow at a CAGR of 6.4% from 2025 to 2032, due to increasing integration of mental health screening in gynecological consultations and the availability of digital self-assessment platforms.

• By Symptoms

On the basis of symptoms, the premenstrual dysphoric disorder market is segmented into depression, intense anger, mood swings, irritability, no interest in usual activities, anxiety, trouble concentrating, appetite changes, feeling out of control, fatigue, cramps and bloating, tension, headache, insomnia, joint or muscle pain, breast tenderness, hot flashes, and others. The depression segment accounted for the largest market share of 31.2% in 2024, as it is one of the most debilitating and commonly reported symptoms, significantly impairing daily functioning and quality of life. Increased awareness about PMDD as a mental health condition has boosted patient reporting of depressive symptoms, leading to earlier intervention.

The fatigue segment is expected to witness the fastest growth rate of 8.7% from 2025 to 2032, driven by growing recognition of physical symptoms in PMDD diagnosis and the integration of fatigue management strategies into treatment plans.

• By Dosage

On the basis of dosage, the premenstrual dysphoric disorder market is segmented into tablet, injection, and others. The tablet segment dominated the market with a share of 64.1% in 2024, owing to the widespread prescription of oral antidepressants, hormonal contraceptives, and NSAIDs, which offer ease of administration and patient compliance.

The injection segment is projected to grow at the fastest CAGR of 7.9% from 2025 to 2032, particularly due to the rising use of injectable hormonal treatments for patients with severe PMDD unresponsive to oral regimens.

• By Route of Administration

On the basis of route of administration, the premenstrual dysphoric disorder market is segmented into oral, intravenous, and others. The oral route held the largest share of 71.4% in 2024, supported by its convenience, non-invasiveness, and high patient adherence for daily or intermittent therapy.

The intravenous segment is anticipated to record notable growth at a CAGR of 6.8% from 2025 to 2032, driven by the use of IV hormonal therapies and supportive treatments in severe or treatment-resistant PMDD cases.

• By End-Users

On the basis of end-users, the premenstrual dysphoric disorder market is segmented into clinic, hospital, and others. The clinic segment dominated the market in 2024 with a share of 49.7%, reflecting the growing role of gynecology and mental health clinics as primary points of care for PMDD patients. These settings facilitate specialized diagnosis and personalized treatment plans.

The hospital segment is projected to expand at the fastest CAGR of 7.2% from 2025 to 2032, fueled by the availability of multidisciplinary care, advanced diagnostic facilities, and inpatient treatment for severe cases.

• By Distribution Channel

On the basis of distribution channel, the premenstrual dysphoric disorder market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment accounted for the largest revenue share of 46.9% in 2024, supported by the ease of access to prescription and over-the-counter PMDD treatments, particularly in urban areas.

The online pharmacy segment is expected to grow at the highest CAGR of 10.1% from 2025 to 2032, propelled by increasing e-commerce penetration, discreet delivery options, and the growing trend of telemedicine prescriptions for PMDD.

Premenstrual Dysphoric Disorder Market Regional Analysis

• North America dominated the premenstrual dysphoric disorder market, accounting for the largest revenue share of 40.5% in 2024, driven by heightened awareness of women’s mental health, better diagnostic capabilities, and access to advanced treatment options
• The region benefits from strong healthcare infrastructure, supportive insurance coverage, and a growing emphasis on early diagnosis of PMDD through routine gynecological and psychiatric evaluations. Increased public health campaigns, such as mental health awareness initiatives and women’s health programs, are also improving diagnosis rates
• In addition, the presence of leading pharmaceutical companies and the introduction of novel antidepressants, hormonal therapies, and cognitive-behavioral therapy (CBT) programs tailored for PMDD are contributing to market growth

U.S. Premenstrual Dysphoric Disorder Market Insight

The U.S. premenstrual dysphoric disorder market captured the largest share of 68% within the North American PMDD market in 2024, largely due to high healthcare expenditure, widespread screening for mood disorders, and active research into novel treatment modalities. Increased adoption of SSRIs, drospirenone-containing oral contraceptives, and emerging non-hormonal therapies has significantly expanded treatment accessibility. The country is witnessing growing collaborations between gynecologists and mental health professionals to create personalized treatment plans. Public awareness campaigns and workplace wellness programs focusing on menstrual health are also boosting early detection and treatment adherence among women of reproductive age.

Europe Premenstrual Dysphoric Disorder Market Insight

The Europe premenstrual dysphoric disorder market is expected to grow steadily during the forecast period, supported by enhanced mental health awareness and stronger government focus on gender-specific healthcare. Initiatives promoting early intervention, coupled with access to both pharmacological and non-pharmacological therapies, are boosting treatment rates. Increasing numbers of clinical trials in countries such as Germany, France, and the U.K. are exploring the effectiveness of combined therapies, including lifestyle interventions alongside medication. The region also benefits from favorable reimbursement policies for mental health treatments, which encourage patients to seek medical attention earlier.

U.K. Premenstrual Dysphoric Disorder Market Insight

The U.K. premenstrual dysphoric disorder market is witnessing growth due to increased national focus on women’s mental health, supported by NHS-funded screening programs and treatment options. Educational campaigns in schools and workplaces are fostering better understanding of PMDD symptoms, encouraging more women to seek diagnosis. The availability of hormonal therapies, coupled with counseling and CBT options, is improving treatment outcomes. Additionally, the U.K. is investing in telehealth services, making it easier for patients in remote areas to access mental health professionals specializing in PMDD.

Germany Premenstrual Dysphoric Disorder Market Insight

Germany’s premenstrual dysphoric disorder market growth is driven by a robust healthcare system, high patient awareness, and emphasis on evidence-based treatment plans. The country has a growing network of women’s health clinics and psychiatric centers offering integrated care for PMDD patients. Pharmaceutical innovation is strong, with local research institutions collaborating with global companies to develop new drug formulations with fewer side effects. Moreover, Germany’s strong mental health advocacy culture supports public education campaigns that reduce stigma and encourage patients to seek timely treatment.

Asia-Pacific Premenstrual Dysphoric Disorder Market Insight

The Asia-Pacific premenstrual dysphoric disorder market region is projected to grow at the fastest CAGR from 2025 to 2032, fueled by rising awareness of mental health disorders, urbanization, and expanding access to healthcare services in countries such as China, Japan, and India. Cultural shifts and increasing openness in discussing menstrual and mental health issues are helping more women come forward for diagnosis and treatment. Governments in the region are investing in public health campaigns, and pharmaceutical companies are expanding distribution networks for PMDD medications. Additionally, the rise of digital health platforms is facilitating virtual consultations, which is particularly beneficial in rural and underserved areas.

Japan Premenstrual Dysphoric Disorder Market Insight

The Japan premenstrual dysphoric disorder market is benefiting from the country’s advanced healthcare infrastructure, high literacy on health issues, and integration of mental health screening in gynecological care. Growing emphasis on work-life balance and women’s wellness programs in corporate settings is also encouraging early treatment. Japanese pharmaceutical companies are actively developing new hormonal and non-hormonal treatments, while traditional medicine options are also being explored in clinical studies. The cultural acceptance of medical intervention for mental health is further accelerating market growth.

China Premenstrual Dysphoric Disorder Market Insight

China premenstrual dysphoric disorder market accounted for the largest market share in the Asia-Pacific PMDD market in 2024, driven by a rapidly growing middle class, improved access to mental health services, and government efforts to expand women’s healthcare programs. The country is experiencing a surge in hospital-based and online consultations for menstrual-related mood disorders. Domestic pharmaceutical companies are expanding the availability of PMDD-specific medications, while awareness campaigns on social media platforms are helping to destigmatize the condition.

Premenstrual Dysphoric Disorder Market Share

The Premenstrual Dysphoric Disorder industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Lilly USA, LLC (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson and its affiliates (U.S.)
• Sanofi (France)
• Bayer AG (Germany)
• Takeda Pharmaceutical Company Limited (Japan)
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
• Bausch Health Companies Inc. (India)

Latest Developments in Global Premenstrual Dysphoric Disorder Market

• In October 2024, Teva Pharmaceuticals received FDA approval for Lysteda (tranexamic acid) as a new treatment option for PMDD, marking a significant step forward in addressing severe symptoms and fulfilling the growing demand for effective therapeutic alternatives
• In 2023, Flo Health, a widely used menstrual tracking app, launched a PMDD symptom-logging feature. This tool enables users to record their symptoms and receive personalized recommendations—including cognitive behavioral therapy modules—effectively bridging symptom tracking with treatment pathways
• In 2023, Asarina Pharma advanced its PMDD-specific treatment candidate sepranolone, a neurosteroid modulator, through a successful Phase IIb trial, demonstrating a 40% reduction in irritability scores among PMDD patients. The company plans to submit an NDA in 2025, positioning sepranolone as potentially the first medication explicitly developed for PMDD

SKU-67056